Brought to you by DIA in cooperation with

Recently, several US states have passed, or are in the process of passing,  new legislation designed to limit drug costs by requiring reporting on drug prices. This includes disclosure of prices of new products, current Wholesale Acquisition Cost (WAC) prices, and drug price increases. These changes have further complicated the data collection and report generation process, leading to regulatory and pricing pressures.

We will discuss the challenges around data management, compliance of State Drug Price Transparency laws, and pragmatic approaches for manufacturers to effectively and efficiently manage the complex reporting process.